GlaxoSmithKline (NYSE:GSK) was downgraded by analysts at TheStreet from a “b-” rating to a “c” rating in a research note issued to investors on Wednesday, February 7th.
Several other equities research analysts have also issued reports on the stock. Zacks Investment Research raised shares of GlaxoSmithKline from a “hold” rating to a “buy” rating and set a $46.00 price objective for the company in a research report on Wednesday, October 18th. UBS Group upgraded shares of GlaxoSmithKline from a “neutral” rating to a “buy” rating and upped their target price for the company from $35.04 to $35.85 in a research note on Monday, November 27th. Barclays upgraded shares of GlaxoSmithKline from an “equal weight” rating to an “overweight” rating in a research note on Tuesday, January 16th. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of GlaxoSmithKline in a research note on Tuesday, October 24th. Finally, Argus dropped their target price on shares of GlaxoSmithKline to $40.00 and set a “buy” rating on the stock in a report on Thursday, November 30th. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating and six have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $38.97.
GlaxoSmithKline (GSK) traded up $0.38 during trading hours on Wednesday, hitting $37.70. 4,690,000 shares of the stock were exchanged, compared to its average volume of 5,070,000. The company has a current ratio of 0.60, a quick ratio of 0.39 and a debt-to-equity ratio of 4.09. The firm has a market capitalization of $91,790.00, a price-to-earnings ratio of 43.33, a PEG ratio of 2.37 and a beta of 0.98. GlaxoSmithKline has a twelve month low of $34.52 and a twelve month high of $44.53.
GlaxoSmithKline (NYSE:GSK) last issued its quarterly earnings results on Wednesday, February 7th. The pharmaceutical company reported $0.72 EPS for the quarter, topping the consensus estimate of $0.69 by $0.03. GlaxoSmithKline had a net margin of 4.97% and a return on equity of 130.63%. The firm had revenue of $10.14 billion during the quarter, compared to analyst estimates of $9.89 billion. equities analysts expect that GlaxoSmithKline will post 2.85 earnings per share for the current year.
Institutional investors and hedge funds have recently made changes to their positions in the business. Sawtooth Solutions LLC boosted its holdings in shares of GlaxoSmithKline by 316.0% during the fourth quarter. Sawtooth Solutions LLC now owns 24,054 shares of the pharmaceutical company’s stock worth $853,000 after purchasing an additional 18,272 shares during the period. Slow Capital Inc. acquired a new stake in shares of GlaxoSmithKline during the fourth quarter worth approximately $724,000. Amussen Hunsaker Associates LLC bought a new position in GlaxoSmithKline during the fourth quarter valued at approximately $141,000. Banco de Sabadell S.A bought a new position in GlaxoSmithKline during the fourth quarter valued at approximately $635,000. Finally, Lincluden Management Ltd. raised its position in GlaxoSmithKline by 29.4% during the fourth quarter. Lincluden Management Ltd. now owns 274,720 shares of the pharmaceutical company’s stock valued at $9,744,000 after acquiring an additional 62,360 shares in the last quarter. Institutional investors own 9.52% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “GlaxoSmithKline (GSK) Stock Rating Lowered by TheStreet” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international copyright law. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/02/18/glaxosmithkline-gsk-downgraded-to-c-at-thestreet.html.
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.